Skip to main content
Clinical Trials/NCT07392619
NCT07392619
Not yet recruiting
Not Applicable

Evaluation of the Effect of Acupressure Applied to Older Adults With Painful Diabetic Peripheral Neuropathy on Neuropathic Symptoms, Balance Confidence, Fear of Falling, and Quality of Life:

Nigde Omer Halisdemir University0 sites76 target enrollmentStarted: December 30, 2026Last updated:

Overview

Phase
Not Applicable
Status
Not yet recruiting
Sponsor
Nigde Omer Halisdemir University
Enrollment
76
Primary Endpoint
DIABETIC NEUROPATHY SYMPTOM SCORE

Overview

Brief Summary

This project aims to evaluate the effects of acupressure applied to elderly individuals with painful diabetic peripheral neuropathy (DPN) on neuropathic symptoms, balance confidence, fear of falling, and quality of life. This project will be conducted using a mixed methodology integrating quantitative and qualitative methods. Elderly individuals will be randomly assigned to an acupressure or placebo control group. The acupressure group will receive a total of 10 sessions of acupressure over one month. Outcome measures include assessments of neuropathic pain and symptoms, balance confidence, fear of falling, and quality of life. Appropriate statistical tests will be used to analyze the quantitative data obtained from the study, while content analysis will be used for the qualitative data.

Detailed Description

To avoid ignoring the increasing disease burden, decreased productivity, and other problems of elderly individuals, it is important to carefully consider GETAT (Traditional and Complementary Medicine) approaches that may be beneficial in controlling their multiple symptoms in this specific group.

This study aims to evaluate the effect of acupressure on neuropathic symptoms, balance confidence, fear of falls, and quality of life in elderly individuals with Painful Diabetic Peripheral Neuropathy (PDN).

This research will be conducted at Niğde Training and Research Hospital. The research population consists of individuals who participate in planned visits to the Internal Medicine outpatient clinics of Niğde Training and Research Hospital, have a prior diagnosis of DM, and have been diagnosed with DPN by a specialist physician.

Individuals in the acupressure group will participate in a program consisting of a total of 10 sessions over one month. Each session will consist of preparation, application, and termination steps.

The acupuncture points to be applied in this research were determined by an experienced acupuncture specialist and the researcher, according to GETAT methods and in line with the literature.

The number, duration, frequency, and application protocol of sessions in the placebo-acupressure group will be the same as in the acupressure group. The only difference between the two groups is the location of the points.

The study will be conducted in accordance with the 1964 Helsinki Declaration. Research will commence after the purpose and methodology of the study are explained to the participants, anonymity and confidentiality are guaranteed, their willingness to participate is confirmed, and participants provide their BOGs (Brain Stability Questionnaire).

Outcome measures include assessment of neuropathic pain and symptoms, balance confidence, fear of falling, and quality of life. Appropriate statistical tests will be used to analyze quantitative data, and content analysis will be used for qualitative data.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Supportive Care
Masking
Triple (Participant, Care Provider, Outcomes Assessor)

Eligibility Criteria

Ages
65 Years to — (Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Elderly individuals aged 65 years and older
  • No sensory impairment that would hinder communication
  • Cognitively capable of answering questions
  • Able to walk independently or with an assistive device
  • Have not previously received acupressure therapy for DPN
  • Diagnosed with diabetic peripheral neuropathy (DPN) by a physician
  • No orthopedic problems
  • Provide informed consent

Exclusion Criteria

  • Not providing informed consent
  • History of non-diabetic neuropathy
  • Physician-diagnosed advanced cardiovascular, kidney, or liver disease
  • Bleeding tendency
  • Cerebrovascular disease
  • History of medical conditions such as retinopathy or nephropathy
  • Presence of open wounds, ulcers, or orthopedic problems on the feet
  • Inability to walk independently
  • Not voluntarily agreeing to participate in the study

Arms & Interventions

Acupressure

Active Comparator

The acupressure group will receive a total of 10 sessions of acupressure over one month.

Intervention: acupressure (Other)

placebo control

Placebo Comparator

For individuals in the placebo (sham) acupressure group, placebo (sham) acupressure will be applied away from the designated acupoint. The number, duration, frequency and application protocol of sessions in the placebo acupressure group will be the same as in the acupressure group.

Intervention: placebo acupressure (Other)

Outcomes

Primary Outcomes

DIABETIC NEUROPATHY SYMPTOM SCORE

Time Frame: 0-4 weeks

Diabetic neuropathy symptoms will be assessed using the Diabetic Neuropathy Symptom Score (DNS) and reported as a total score (points).The Diabetic Neuropathy Symptom Score will be used to assess participants' diabetic neuropathy symptoms. It consists of four questions related to gait imbalance, neuropathic pain, paresthesia, and numbness. Each question is scored from 0 (none) to 1 (yes), and a total score is calculated. The maximum score is 4 points, and a score of 1 or higher is defined as positive for DPN.

Neuropathic Pain Scale

Time Frame: 0-4 weeks

Neuropathic pain level will be measured using the Self-Administered Leeds Assessment of Neuropathic Symptoms and Signs (S-LANSS) questionnaire and reported as a score (points). In this study, the Self-Administered-Leeds Assessment of Neuropathic Symptoms and Signs Pain Score (S-LANSS) will be used to evaluate neuropathic pain. Participants will respond "yes" if the pain symptom is consistent with the description, and "no" if the pain symptom is inconsistent. The total score is scored between 0 and 24. The cutoff value is 12, and if the total score is ≥12, neuropathic mechanisms may be responsible for the pain experienced by the patient.

Secondary Outcomes

  • BALANCE CONFIDENCE SCALE(0-4 weeks)
  • European General Quality of Life Scale (EQ-5D).(0-4 weeks)

Investigators

Sponsor
Nigde Omer Halisdemir University
Sponsor Class
Other
Responsible Party
Sponsor

Similar Trials